Biomarker Identification for Bladder Cancer Patients
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Bladder Cancer
- Sponsor
- Ohio State University Comprehensive Cancer Center
- Enrollment
- 179
- Locations
- 1
- Primary Endpoint
- Identify novel biomarkers for bladder cancer
- Status
- Terminated
- Last Updated
- last year
Overview
Brief Summary
To develop a simple blood and urine test that we would perform before patients start their treatment to predict the risk that their bladder cancer might come back. To develop this test the investigators plan to analyze blood, urine and cancer tissue from bladder cancer patients and follow them closely during and after treatment. This will include looking for changes in proteins and genes that might play a role in bladder cancer biology. The investigators will then compare the information obtained from the studies of blood, urine and cancer tissue between patients that are cured and those whose cancer comes back. The knowledge about these differences between patients can then potentially be used to develop a blood or urine test to tell us who has a high risk for having bladder cancer come back.
Investigators
Arnab Chakravarti
Principal Investigator
Ohio State University Comprehensive Cancer Center
Eligibility Criteria
Inclusion Criteria
- •Adult patients ≥18 years old.
- •Patients suspected, clinically diagnosed, or histologically diagnosed bladder cancer.
- •Patients undergoing cystoscopy without cancer suspicion.
- •Ability to give an informed consent.
Exclusion Criteria
- •Patients receiving concurrent therapy for a second malignancy.
- •\< 18 years old.
- •Inability to give an informed consent.
Outcomes
Primary Outcomes
Identify novel biomarkers for bladder cancer
Time Frame: up to 5 years
Predict and detect bladder cancer recurrence, specifically through development of biomarkers using bladder cancer tissue samples as well as blood and urine samples. Detect the recurrence of disease through development of blood and urine biomarkers using pre-therapy and post-therapy biospecimens.